Original articleAlimentary tractEffect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea
-
Add time:08/28/2019 Source:sciencedirect.com
Background & AimsRamosetron, a serotonin (5-hydroxytryptamine)-3 receptor antagonist with high selectivity, reduced stress-induced diarrhea and defecation caused by corticotropin-releasing hormone in rats. However, there have been no clinical trials of its effect in patients with diarrhea and irritable bowel syndrome (IBS-D). We performed a randomized, double-blind, placebo-controlled trial to determine whether ramosetron reduces diarrhea in these patients.
We also recommend Trading Suppliers and Manufacturers of Ramosetron hydrochloride (cas 132907-72-3). Pls Click Website Link as below: cas 132907-72-3 suppliers
Prev:Mucoadhesive suppositories of Ramosetron hydrochloride (cas 132907-72-3) utilizing Carbopol®
Next:Original ResearchFull Report: Clinical—Alimentary TractRamosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study09/04/2019
- Prophylactic Antiemetic Efficacy of Granisetron or Ramosetron in Patients Undergoing Thyroidectomy09/03/2019
- Full PaperInhibitory Effects of Ramosetron, a Potent and Selective 5-HT3–Receptor Antagonist, on Conditioned Fear Stress–Induced Abnormal Defecation and Normal Defecation in Rats: Comparative Studies With Antidiarrheal and Spasmolytic Agents09/02/2019
- Full PaperEvaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome09/01/2019
- Oral formulations of the selective serotonin3 antagonists ramosetron (intraoral disintegrator formulation) and granisetron hydrochloride (standard tablet) in treating acute chemotherapy-induced emesis, nausea, and anorexia: A multicenter, randomized, single-blind, crossover, comparison study08/31/2019
- Pulmonary, gastrointestinal and urogenital pharmacologyInhibitory effect of the selective serotonin 5-HT3 receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats08/30/2019
- Original ResearchFull Report: Clinical—Alimentary TractRamosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women08/29/2019
- Mucoadhesive suppositories of Ramosetron hydrochloride (cas 132907-72-3) utilizing Carbopol®08/27/2019
-
Health and Chemical more >